Celularity CEO Comments on Centers for Medicare & Medicaid Services Withdrawal of Skin Substitute Local Coverage Determinations
While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage…
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 31, 2025 16:30 ET | Source: FibroBiologics, Inc. Advancing preparations to…